Detalhe da pesquisa
1.
Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease.
J Pharmacol Exp Ther
; 380(3): 210-219, 2022 03.
Artigo
Inglês
| MEDLINE | ID: mdl-35031585
2.
Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease.
Blood Adv
; 2024 Apr 19.
Artigo
Inglês
| MEDLINE | ID: mdl-38640200
3.
Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial.
Neuro Oncol
; 25(1): 146-156, 2023 01 05.
Artigo
Inglês
| MEDLINE | ID: mdl-35639513
4.
Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.
Lancet Haematol
; 10(1): e46-e58, 2023 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-36370742
5.
Safety, Pharmacokinetics, and Pharmacodynamics of Etavopivat (FT-4202), an Allosteric Activator of Pyruvate Kinase-R, in Healthy Adults: A Randomized, Placebo-Controlled, Double-Blind, First-in-Human Phase 1 Trial.
Clin Pharmacol Drug Dev
; 11(5): 654-665, 2022 05.
Artigo
Inglês
| MEDLINE | ID: mdl-35019238